Abstract:Objective To investigate the clinical risk factors related to the cirrhosis development in patients with hepatitis B virus infection. Methods A total of 988 participants with hepatitis B virus infection were collected for this study in Zhong Shan Hospital affiliated with Fu Dan University between January 2009 and January 2011. All of them were Chinese Han nationality from Shanghai and its surrounding area. Their information, including hepatitis history, serum test, liver imaging, and liver histology if available, were collected. They were divided into healthy recovered and chronic hepatitis group, the later was subdivided into cirrhotic group and non-cirrhotic group. The general informations and clinical determination datas were compared with statistical analysis by using SPSS 18.0 and STATA 11.0 software. Results (1) The ratio of male/female participants was 736/252, and the average age was 50.8±13.2. The numbers of participants in healthy recovered group, non-cirrhotic chronic hepatitis and cirrhotic group were 274, 285, and 429, respectively, and the average ages were 56.7±13.6, 49.2±11.5, and 47.5±13.5, respectively. Chronic hopatitis B (CHB) familial history was found in 2.2% participants of the healthy recovered group and 47.5% participants of chronic hepatitis group. The vertical infection rates were 56.3% in healthy recovered group, and 93.7% in chronic hepatitis group, which have significant difference between them. For chronic hepatitis group, the vertical rates of non-cirrhotic and cirrhotic group were 89.4% and 96.4%, respectively, which also have significant difference between them. The vertical infection was a risk factor for chronicity of hepatitis B (OR=15.02, 95% CI:9.57-23.94) and the development of cirrhosis (OR=3.15, 95%CI:1.39-7.45). The duration of disease of cirrhotic patients (44.1±9.5 years) was longer than that of non-cirrhotic CHB patients (39.3±9.8 years). The ratio of male patients in cirrhotic group was also significantly higher than that in non-cirrhotic group (70.2%) and the duration of disease for male patients (41.7±9.3 years) were shorter than that of female patients (45.0±11.4 years).(2) The levels of liver function rests were significantly different among healthy recover, non-cirrhotic, and cirrhotic group of CHB patients. There were negative correlation between HBsAg and HBV DNA in HBeAg positive patients (r=-0.43);However positive correlation in HBeAg negative patients (r=0.23) was observed. HBsAg level, which was higher than 1 000 COI, of cirrhotic patients (89.5%) was significant higher than that of non-cirrhotic patients (89.5%) (OR=1.86, 95% CI:1.18-2.94). No correlation was found betweem HBV DNA level and the duration of disease of CHB (P=0.21). Although HBV DNA level in cirrhotic group was significantly higher than that in non-cirrhotic group (2.875±2.68 log10copies/mL), the ratio of patients with HBV DNA level, which was higher than 5 log10copies/mL in cirrhotic group (31%) was significantly lower than that in non-cirrhotic group(57.2%). Conclusion The factors associated with cirrhosis development in CHB patients include duration of diseases, familial history, route of infection (vertical infection), male gender, the level of HBsAg(higher than 1 000 COI), and HBV DNA level.

Plenary Presentation

Metabolic Syndrome Increases the Risk of Liver Cirrhosis in Chronic Hepatitis B

A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry.

Prevalence of Hepatic Steatosis, Fibrosis and Associated Factors in Chronic Hepatitis B

Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study

Concurrence and Impact of Hepatic Steatosis on Chronic Hepatitis B Patients: a Systematic Review and Meta-Analysis

Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC

Characterizing Unique Clinical and Virological Profiles in Concurrent Chronic Hepatitis B and Metabolic Dysfunction-Associated Liver Disease: Insights from a Population-Based Cohort Study

Supplementary Material For: Increased Risk of Liver-Related Outcomes in Chronic Hepatitis B Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis

Clinical characteristics of chronic hepatitis B patients with metabolic syndrome

Development and Validation of a Non-Invasive Model for Predicting Liver Cirrhosis in Patients with Chronic Hepatitis B

Long-term Risks for Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes

Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease

Evaluation of the clinical risk factors associated with liver cirrhosis in patients with chronic hepatitis B viral infection

Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B

Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients

Serum Lipid Alterations Identified in Chronic Hepatitis B, Hepatitis B Virus-Associated Cirrhosis and Carcinoma Patients

Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers

Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis

Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study

Assessment of HBV variants and novel viral and immune biomarkers in chronic hepatitis B patients with metabolic dysfunction associated steatotic liver disease